Skip to main content
B

Boji Medical Technology Co., Ltd. — Investor Relations & Filings

Ticker · 300404 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,800 across all filing types
Latest filing 2026-04-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300404

About Boji Medical Technology Co., Ltd.

https://www.gzboji.com

Boji Medical Technology Co., Ltd. is a comprehensive contract research organization (CRO) providing full-service solutions for pharmaceutical and medical device development. The company specializes in clinical research services, including Phase I through IV clinical trials, bioequivalence studies, and post-marketing surveillance. Its service portfolio encompasses drug registration, medical writing, data management, and statistical analysis. Boji Medical supports clients through the entire product lifecycle, from preclinical research and regulatory consulting to clinical trial management and market authorization. The organization focuses on maintaining high standards of quality and compliance with international regulatory requirements, facilitating the development of innovative therapies and medical technologies for global biotechnology and pharmaceutical sectors.

Recent filings

Filing Released Lang Actions
关于为子公司提供融资担保的公告
Capital/Financing Update Classification · 1% confidence The document is a formal disclosure by a listed company (ticker 300404) regarding its board and shareholders’ approval to provide financing guarantees for subsidiaries. It outlines guarantee amounts, terms, and subsidiary financial data. This is not an earnings release, AGM materials, management change, or a published report, but an update on the company’s financing activities (providing loan guarantees). Therefore, it best fits the Capital/Financing Update category (CAP).
2026-04-24 Chinese
关于向金融机构申请融资授信额度的公告
Capital/Financing Update Classification · 1% confidence The document is titled as an announcement regarding the company’s application for financing credit facilities with banks and non-bank financial institutions. It details the proposed total credit limit, types of credit lines, collateral arrangements, and board/ shareholder authorisations. This is not a financial report or earnings release but a financing activity update. Therefore, it falls under Capital/Financing Update (Code: CAP).
2026-04-24 Chinese
关于非经营性资金占用及其他关联资金往来情况的专项审核说明
Audit Report / Information Classification · 1% confidence The document is issued by a certified public accounting firm (Guangdong Sinong CPA) under CPA auditing standards, entitled “专项审核说明” (special audit explanation) regarding non-operating fund occupation and related-party transactions for the 2025 year. It references the audit of the company’s financial statements, includes the audit procedures applied, and provides detailed audited tables. It is not merely an announcement of a report (RPA), nor a full annual or interim report. It is a standalone audit report on a specific matter in line with the “Audit Report / Information” definition.
2026-04-24 Chinese
2025年度募集资金存放、管理与使用情况的专项报告
Capital/Financing Update Classification · 1% confidence The document is a detailed “募集资金存放、管理与使用情况专项报告” (special report on the storage, management and use of proceeds raised in a prior A-share issuance). It contains the fundraising amount, net proceeds, specific use of funds by project, changes or terminations of projects, and compliance with exchange rules. It is not an earnings announcement or annual/interim report, but an ongoing regulatory update on the use of raised capital. This aligns with the “Capital/Financing Update” category (CAP).
2026-04-24 Chinese
公司2025年度非经营性资金占用及其他关联资金往来情况汇总表
Financial Supplement Data Classification · 1% confidence The document is a standalone summary table (“汇总表”) detailing non-operating fund occupation and related-party fund transactions for the year 2025. It is not a full report (e.g., 10-K or interim report), nor a simple announcement or press release. Instead, it presents tabulated financial schedules akin to supplementary data one might provide in an Excel exhibit. Therefore, it best fits the “Financial Supplement Data” category (XLSX).
2026-04-24 Chinese
董事会对独立董事独立性自查情况的专项报告
Governance Information Classification · 1% confidence The document is a special board report on the self-assessment of independent directors’ independence, prepared under listing rules and internal governance requirements. It does not announce any board changes (so not MANG) nor is it a financial or audit report. It is a corporate governance disclosure detailing governance practices and compliance with the independent director rules, fitting the Governance Information category (CGR).
2026-04-24 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.